Home > Financial Ratios > CORONA REMEDIES

CORONA REMEDIES
Core EBITDA Margin

    Back to All Ratios
CORONA REMEDIES is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
COMMUNITY POLL
for CORONA REMEDIES
Please provide your vote to see the results

CORONA REMEDIES Last 5 Year Core EBITDA Margin History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023
   Core EBITDA Margin(%) 21.2720.4214.9214.25

What is the latest Core EBITDA Margin ratio of CORONA REMEDIES ?

The latest Core EBITDA Margin ratio of CORONA REMEDIES is 21.27 based on Mar2026 Consolidated results.
Year Core EBITDA Margin
Mar202621.27
Mar202520.42
Mar202414.92
Mar202314.25

How is Core EBITDA Margin of CORONA REMEDIES Trending?

Years Core EBITDA Margin % Change
Mar2026 21.27
4.16
Mar2025 20.42
36.86
Mar2024 14.92
4.70
Mar2023 14.25 -

Other Financial Ratios of CORONA REMEDIES


Compare Core EBITDA Margin ratio of peers of CORONA REMEDIES

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
CORONA REMEDIES ₹12,326.6 Cr -1.2% -8% NA Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹422,067.0 Cr -2.3% -5.9% 6.2% Stock Analytics
DIVIS LABORATORIES ₹248,983.0 Cr -1.7% -1.1% 60.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹177,974.0 Cr -2.1% -5.1% 32.2% Stock Analytics
CIPLA ₹106,130.0 Cr -2.2% -4% -13.9% Stock Analytics
DR REDDYS LABORATORIES ₹102,707.0 Cr 1.8% 7.6% -4.3% Stock Analytics


CORONA REMEDIES Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
CORONA REMEDIES

-1.2%

-8%

NA
SENSEX

-0.6%

-4.8%

-11.4%


You may also like the below Video Courses